Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
Authors
Eisen, TMarais, R
Affolter, A
Lorigan, Paul C
Robert, C
Corrie, P
Ottensmeier, C
Chevreau, C
Chao, D
Nathan, P D
Jouary, T
Harries, M
Negrier, S
Montegriffo, E
Ahmad, T
Gibbens, I
James, M G
Strauss, U P
Prendergast, S
Gore, M E
Affiliation
Department of Oncology (R4), Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK. tgqe2@cam.ac.ukIssue Date
2011-07-26
Metadata
Show full item recordAbstract
The safety of oral sorafenib up to a maximum protocol-specified dose combined with dacarbazine in patients with metastatic, histologically confirmed melanoma was investigated in a phase I dose-escalation study and the activity of the combination was explored in an open-label phase II study.Citation
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. 2011, 105 (3):353-9 Br. J. CancerJournal
British Journal of CancerDOI
10.1038/bjc.2011.257PubMed ID
21750549PubMed Central ID
PMC3172912Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2011.257